The distribution of hepatitis C viral genotypes shifted among chronic hepatitis C patients in Yunnan, China, between 2008-2018.


Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2023
Historique:
received: 08 11 2022
accepted: 13 06 2023
medline: 28 7 2023
pubmed: 27 7 2023
entrez: 27 7 2023
Statut: epublish

Résumé

The hepatitis C virus (HCV) is prevalent across China, with a distinctive genotypic distribution that varies by geographical region and mode of transmission. Yunnan is one such geographical region wherein the local population continues to experience a high level of HCV infection, severely straining public health resources. This high prevalence is likely due to the increased incidence of intravenous drug use in that region, as Yunnan is a major point of entry for illegal heroin into China. We investigated 510 individuals with chronic HCV infections in Yunnan Province from 2008 through 2018. Using reverse transcription PCR and Sanger sequencing to amplify and sequence samples. Bayesian analyses was performed to estimate the common ancestors and Bayesian skyline plot to estimate the effective viral population size. Molecular network was conducted to explore the characteristics of HCV transmission. We successfully amplified and sequenced a total of 503 viral samples and genotyped each as either 3b (37.6%), 3a (21.9%), 1b (19.3%), 2a (10.5%), HCV-6 (10.1%), or 1a (0.6%). Over this 11-year period, we observed that the proportion of 3a and 3b subtypes markedly increased and, concomitantly, that the proportion of 1b and 2a subtypes decreased. We also performed Bayesian analyses to estimate the common ancestors of the four major subtypes, 1b, 2a, 3a, and 3b. Finally, we determined that our Bayesian skyline plot and transmission network data correlated well with the changes we observed in the proportions of HCV subtypes over time. Taken together, our results indicate that the prevalence of HCV 3a and 3b subtypes is rapidly increasing in Yunnan, thus demonstrating a steadily growing public health requirement to implement more stringent preventative and therapeutic measures to curb the spread of the virus.

Identifiants

pubmed: 37496804
doi: 10.3389/fcimb.2023.1092936
pmc: PMC10366605
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1092936

Informations de copyright

Copyright © 2023 Jia, Zou, Yue, Liu, Yue, Liu, Liu, Huang, Feng and Xia.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Microbiol Spectr. 2021 Sep 3;9(1):e0029721
pubmed: 34479413
J Hepatol. 2020 Dec;73(6):1548-1556
pubmed: 32777323
J Viral Hepat. 2017 Jul;24(7):551-560
pubmed: 28092412
J Med Virol. 2008 Jul;80(7):1142-52
pubmed: 18461611
J Viral Hepat. 2017 May;24(5):404-411
pubmed: 27882678
Arch Virol. 2019 Jul;164(7):1761-1770
pubmed: 31065852
Expert Rev Anti Infect Ther. 2019 Oct;17(10):763-773
pubmed: 31578079
J Infect Dis. 2018 Oct 20;218(11):1722-1729
pubmed: 29982508
Emerg Microbes Infect. 2021 Dec;10(1):1919-1930
pubmed: 34498547
World J Gastroenterol. 2015 Apr 7;21(13):3904-11
pubmed: 25852275
Cell Physiol Biochem. 2016;39(1):316-30
pubmed: 27352005
Virol J. 2017 Feb 23;14(1):41
pubmed: 28231805
Can J Gastroenterol Hepatol. 2022 Apr 29;2022:7395506
pubmed: 35531123
J Infect. 2020 Apr;80(4):469-496
pubmed: 31790705
J Infect Dis. 2016 Mar 15;213(6):957-65
pubmed: 26582955
PLoS One. 2013 Dec 17;8(12):e82598
pubmed: 24358211
J Virus Erad. 2022 Jun 15;8(2):100071
pubmed: 35757658
J Virol. 2014 Jul;88(13):7120-9
pubmed: 24719413
Transfusion. 1999 Aug;39(8):913
pubmed: 10504132
PLoS One. 2016 Sep 22;11(9):e0163062
pubmed: 27657722
Hepat Mon. 2012 Mar;12(3):196-204
pubmed: 22550528
Infect Drug Resist. 2022 Nov 03;15:6463-6470
pubmed: 36353379
BMC Infect Dis. 2021 Sep 18;21(1):974
pubmed: 34536999
J Med Virol. 2016 Mar;88(3):498-505
pubmed: 26288243
Viruses. 2022 Jul 11;14(7):
pubmed: 35891494
Emerg Microbes Infect. 2017 Nov 1;6(11):e95
pubmed: 29089588
Infect Genet Evol. 2015 Jul;33:101-9
pubmed: 25917496
Infect Genet Evol. 2013 Dec;20:225-9
pubmed: 24012950

Auteurs

Yuanyuan Jia (Y)

Faculty of Life Science and Technology & The Affiliated Anning First People's Hospital, Kunming University of Science and Technology, Kunming, China.

Xiu Zou (X)

Faculty of Life Science and Technology & The Affiliated Anning First People's Hospital, Kunming University of Science and Technology, Kunming, China.

Wei Yue (W)

Department of Infectious Disease, Yunnan Provincial Key Laboratory of Clinical Virology, The First People's Hospital of Yunnan Province, Kunming, China.

Jin Liu (J)

Faculty of Life Science and Technology & The Affiliated Anning First People's Hospital, Kunming University of Science and Technology, Kunming, China.

Ming Yue (M)

Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Yang Liu (Y)

Faculty of Life Science and Technology & The Affiliated Anning First People's Hospital, Kunming University of Science and Technology, Kunming, China.

Li Liu (L)

Faculty of Life Science and Technology & The Affiliated Anning First People's Hospital, Kunming University of Science and Technology, Kunming, China.

Peng Huang (P)

Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.

Yue Feng (Y)

Faculty of Life Science and Technology & The Affiliated Anning First People's Hospital, Kunming University of Science and Technology, Kunming, China.

Xueshan Xia (X)

Faculty of Life Science and Technology & The Affiliated Anning First People's Hospital, Kunming University of Science and Technology, Kunming, China.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH